Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Pediatrics
Volume 2016, Article ID 9648043, 4 pages
http://dx.doi.org/10.1155/2016/9648043
Case Report

A Child with Local Lipohypertrophy following Recombinant Human Growth Hormone Administration

1Department of Pediatric Gastroenterology, Emma Children’s Hospital, Academic Medical Center, Amsterdam, Netherlands
2Pediatric Surgical Centre Amsterdam, VUMC/Emma Children’s Hospital, Academic Medical Center, Amsterdam, Netherlands
3Department of Pediatric Endocrinology, Emma Children’s Hospital, Academic Medical Center, Amsterdam, Netherlands

Received 7 July 2016; Accepted 19 September 2016

Academic Editor: Ashraf T. Soliman

Copyright © 2016 Ilan J. N. Koppen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Cázares-Delgadillo, A. Ganem-Rondero, and Y. N. Kalia, “Human growth hormone: new delivery systems, alternative routes of administration, and their pharmacological relevance,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 78, no. 2, pp. 278–288, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. J. O. L. Jørgensen, H. Nørrelund, F. Conceicao, N. Møller, and J. S. Christiansen, “Somatropin and glucose homeostasis: considerations for patient management,” Treatments in Endocrinology, vol. 1, no. 4, pp. 229–234, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Touraine, G. A. D'Souza, I. Kourides et al., “Lipoatrophy in GH deficient patients treated with a long-acting pegylated GH,” European Journal of Endocrinology, vol. 161, no. 4, pp. 533–540, 2009. View at Publisher · View at Google Scholar
  4. A. Büyükgebiz, A. Aydin, B. Dündar, and K. Yörükoğlu, “Localized lipoatrophy due to recombinant growth hormone therapy in a child with 6.7 kilobase gene deletion isolated growth hormone deficiency,” Journal of Pediatric Endocrinology and Metabolism, vol. 12, no. 1, pp. 95–97, 1999. View at Publisher · View at Google Scholar · View at Scopus
  5. R. H. A. Ruvalcaba and G. B. Kletter, “Abdominal lipohypertrophy caused by injections of growth hormone: a case report,” Pediatrics, vol. 102, no. 2, pp. 408–410, 1998. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Mersebach and U. F. Feldt-Rasmussen, “Localized lipohypertrophy during growth hormone therapy,” Ugeskrift for Laeger, vol. 164, no. 14, pp. 1930–1932, 2002. View at Google Scholar · View at Scopus
  7. L. S. Conwell, E. Pope, A. M. Artiles, A. Mohanta, A. Daneman, and D. Daneman, “Dermatological complications of continuous subcutaneous insulin infusion in children and adolescents,” Journal of Pediatrics, vol. 152, no. 5, pp. 622–628, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. G. S. Babar, O. Ali, E. A. Parton, R. G. Hoffmann, and R. Alemzadeh, “Factors associated with adherence to continuous subcutaneous insulin infusion in pediatric diabetes,” Diabetes Technology and Therapeutics, vol. 11, no. 3, pp. 131–137, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. E. Gandolfi and A. Thione, “A case of insulin lipohypertrophy in a young diabetic female successfully treated by vibroliposuction,” Journal of Plastic, Reconstructive and Aesthetic Surgery, vol. 62, no. 12, pp. e601–e603, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Maffei, C. Martini, C. Pagano, N. Sicolo, and F. Corbetti, “Lipohypertrophy in acromegaly induced by the new growth hormone receptor antagonist pegvisomant,” Annals of Internal Medicine, vol. 145, no. 4, pp. 310–312, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. V. S. Bonert, L. Kennedy, S. Petersenn, A. Barkan, J. Carmichael, and S. Melmed, “Lipodystrophy in patients with acromegaly receiving pegvisomant,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 9, pp. 3515–3518, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. V. Rochira, L. Zirilli, C. Diazzi, S. Romano, and C. Carani, “Clinical and radiological evidence of the recurrence of reversible pegvisomant-related lipohypertrophy at the new site of injection in two women with acromegaly: a case series,” Journal of Medical Case Reports, vol. 6, article 2, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Marazuela, E. Daudén, E. Ocón, D. Moure, and L. Nattero, “Pegvisomant-induced lipohypertrophy: report of a case with histopathology,” Annals of Internal Medicine, vol. 147, no. 10, pp. 741–743, 2007. View at Google Scholar · View at Scopus